The same HUMIRA efficacy and safety profile
you’ve come to count on
All presentations of HUMIRA originate from the same master cell line1,2
The same active ingredient patients and HCPs like you have counted on for over 15 years1‑3
Thinner needle (29 gauge vs 27 gauge)4
50% less volume1
The same therapeutic amount of HUMIRA is now injected in half the volume (for the HUMIRA 40 mg dosage form, the volume is 0.4 mL instead of 0.8 mL)
Modifications to the Pen1
The HUMIRA Citrate‑free Pen now has a larger viewing window and white numbers on the Pen caps
Revised packaging
HUMIRA Citrate‑free comes in a blue box
Less pain immediately following injection4,†
No citrate buffers1,4
Sodium citrate, known to cause pain,5‑8 and other inactive ingredients have been removed
Needle cover not made with natural rubber latex1
For both the HUMIRA Pen and Prefilled* Syringe
*The instructions for storing HUMIRA Citrate-free are not affected by the removal of inactive ingredients, change in volume, or modifications to the Pen. Although the injection may feel different, patients should continue to follow proper injection technique.
†Injection site pain immediately following injection as measured using a 0‑10 cm Visual Analog Scale: HUMIRA 40 mg/0.4 mL vs HUMIRA 40 mg/0.8 mL.
Before HUMIRA is self-injected, instruct the patient on proper injection technique and monitor as necessary. Refer the patient to Medication Guide for proper storage.
Adam was hesitant to ask his doctor about HUMIRA Citrate-free. Now that he’s transitioned, he wishes he’d asked sooner. Hear why.
Advise your patients that pain immediately following injection may now be reduced4
Inform patients that although the injection may feel different, they should continue to follow proper injection technique
Patients should confirm the injection is complete before removing the Pen or Syringe
Instruct your patients to look for the blue box, featuring the 29 gauge needle
Let patients know that HUMIRA Complete is available to provide one‑to‑one personalized support, education, and resources at no extra cost
Inform patients that HUMIRA Citrate‑free has the same efficacy and safety profile they’ve come to count on with HUMIRA, as it has the same active ingredient1,2
The recommended HUMIRA Citrate-free dose regimen for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis is shown below:
EOW=every other week; NDC=National Drug Code
Rheumatoid Arthritis: HUMIRA is indicated, alone or in combination with methotrexate or other non-biologic DMARDs, for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Psoriatic Arthritis: HUMIRA is indicated, alone or in combination with non-biologic DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
Ankylosing Spondylitis: HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
The recommended HUMIRA Citrate‑free dose regimen for adults with non‑infectious intermediate, posterior, and panuveitis is shown below:
*Administered as one 80 mg injection
EOW=every other week; NDC=National Drug Code
Uveitis: HUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
The recommended dose of HUMIRA for pediatric patients 2 years of age and older with polyarticular juvenile idiopathic arthritis (JIA) or with NI intermediate, posterior, or panuveitis is based on weight as shown below. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment with HUMIRA.
HUMIRA has not been studied in patients with JIA less than 2 years of age or in patients with a weight below 10 kg
EOW=every other week; MTX=methotrexate; NDC=National Drug Code; NSAID=nonsteroidal anti-inflammatory drug
Juvenile Idiopathic Arthritis: HUMIRA is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Uveitis: HUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
Rheumatoid Arthritis (RA): HUMIRA is indicated, alone or in combination with methotrexate or other non‑biologic DMARDs, for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Juvenile Idiopathic Arthritis (JIA): HUMIRA is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Psoriatic Arthritis (PsA): HUMIRA is indicated, alone or in combination with non‑biologic DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
Ankylosing Spondylitis (AS): HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
Uveitis (UV): HUMIRA is indicated for the treatment of non‑infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Discontinue HUMIRA if a patient develops a serious infection or sepsis.
Reported infections include:
Carefully consider the risks and benefits of treatment with HUMIRA prior to initiating therapy in patients: 1. with chronic or recurrent infection, 2. who have been exposed to TB, 3. with a history of opportunistic infection, 4. who resided in or traveled in regions where mycoses are endemic, 5. with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including HUMIRA. Postmarketing cases of hepatosplenic T‑cell lymphoma (HSTCL), a rare type of T‑cell lymphoma, have been reported in patients treated with TNF blockers, including HUMIRA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6‑mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants.
Rheumatoid Arthritis (RA): HUMIRA is indicated, alone or in combination with methotrexate or other non‑biologic DMARDs, for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Juvenile Idiopathic Arthritis (JIA): HUMIRA is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Psoriatic Arthritis (PsA): HUMIRA is indicated, alone or in combination with non‑biologic DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
Ankylosing Spondylitis (AS): HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
Adult Crohn's Disease (CD): HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy, and reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.
Pediatric Crohn's Disease: HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6‑mercaptopurine, or methotrexate.
Ulcerative Colitis (UC): HUMIRA is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine, or 6‑mercaptopurine. The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to anti‑TNF agents.
Plaque Psoriasis (Ps): HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow‑up visits with a physician.
Hidradenitis Suppurativa (HS): HUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
Uveitis: HUMIRA is indicated for the treatment of non‑infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
Please see full Prescribing Information.
References: 1. HUMIRA Injection [package insert]. North Chicago, IL: AbbVie Inc. 2. Tebbey PW, Varga A, Naill M, Clewell J, Venema J. Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab). MAbs. 2015;7(5):805‑811. 3. US Food and Drug Administration. HUMIRA (BLA 125057) 4. Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40 mg/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3(2):257‑270. 5. Taub KJ, Blake PG, Langlois S, Jindal KK. A double blind, randomized, crossover study of the local tolerability of erythropoietin alfa formulations in dialysis patients. Can J Hosp Pharm. 1999;52:24‑29. 6. Boyce MJ, Warrington SJ. A comparison of the discomfort from subcutaneous injection of 0.4 mL vs. 1.0 mL citrate buffered epoetin alfa. Br J Clin Res. 1995;6:209‑212. 7. Veys N, Dhondt A, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin: phosphate‑buffered epoetin alpha compared to citrate‑buffered epoetin alpha and epoetin beta. Clin Nephrol. 1998;49(1):41‑44. 8. Yu AW, Leung CB, Li PKT, Lui SF, Lai KN. Pain perception following subcutaneous injections of citrate buffered and phosphate buffered epoetin alpha. Int J Artif Organs. 1998;21(6):341‑343.